News

Recent performance snapshot Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with a gain of 2.7% over the past day contrasted with a decline of 6.5% over the past month. See our latest analysis for Novo Nordisk. Zooming out, Novo Nordisk’s recent bounce comes after a softer patch, with the share price up over the past quarter but down year to date, while the 1 year total shareholder return is also lower. This suggests momentum has cooled compared with...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $43.93, denoting a +2.62% move from the preceding trading day.

Novo Nordisk (NYSE:NVO) is one of the top large cap value stocks to buy now. On June 8, Novo Nordisk presented Phase 3 results from its REIMAGINE 1–3 clinical program at the 2026 American Diabetes Association Scientific Sessions. The trials showed that the investigational treatment CagriSem, a once-weekly combination of an amylin analog and a […]

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

Novo Nordisk revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy pill, following in the footsteps of the U.S. FDA.

Novo Nordisk reported an IT security incident involving unauthorized access to internal systems. Certain non public, including personal, data was copied externally, prompting notifications to affected parties. Some IT systems were taken offline in response, while the company stated that business operations were unaffected. Novo Nordisk, traded as CPSE:NOVO B, is addressing this cybersecurity incident against a backdrop of recent share price pressure. The stock closed at DKK281.2, with the...

The U.K. regulator is the third regulatory authority to license the medicine as the Danish drugmaker seeks to regain its lead in the obesity market.

Rising use of weight-loss drugs keeps pressure on health benefit costs.

Novo Nordisk said on Thursday it has ‌identified a security incident involving ‌unauthorized access to a limited number ​of internal IT systems. The company's core business operations are not impacted and remain ​up ‌and running, it added.

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker

Find insight on Big European pharmaceutical companies, GSK, Kossan Rubber Industries and more in the latest Market Talks covering the health care sector.

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

European equities traded in the US as American depositary receipts were tracking lower late Tuesday

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to

Recent performance snapshot Novo Nordisk (CPSE:NOVO B) has seen mixed share performance, with the stock down 0.7% over the past day and 2.8% over the past week, but up 8.1% over the past 3 months. Over longer periods the picture is more challenging, with the stock down over the past month, year to date, and past year, while still showing a gain over the past 5 years. This provides important context before looking at fundamentals. See our latest analysis for Novo Nordisk. At a share price of...

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

The milestone shows strong early demand as Novo competes with Lilly in oral weight-loss drugs.

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.

Novo's CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.

Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Hated Moats’s Substack by Hated Moats Investors. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $42.96 as of June 5th. NVO’s trailing and forward P/E were 10.09 and 12.77 […]